Posted by Michael Wonder on 08 Mar 2024
ICER to assess treatments for transthyretin amyloidosis cardiomyopathy
7 March 2024 - Report will be subject of Midwest CEPAC meeting in September 2024; draft scoping document open to public comment until 27 March 2024.
The ICER announced today that it will assess the comparative clinical effectiveness and value of acoramidis (BridgeBio Pharma), tafamidis (Pfizer) and vutrisiran (Alnylam Pharmaceuticals) for the treatment of transthyretin amyloidosis cardiomyopathy.
